Would the Bass and Spangenberg ‘invest and invalidate’ strategy work with Chinese patents?

Since teaming up with former IPNav CEO Erich Spangenberg to launch their first US inter partes review (IPR) in February last year – challenging a pharmaceutical dosage-related patent owned by Acorda Therapeutics – Kyle Bass has become one of the IP…

Get unlimited access to all IAM content